Topic use of dutasteride for treatment of androgenic alopecia in | 1518
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

Topic use of dutasteride for treatment of androgenic alopecia in male and female: A controlled pilot study

2nd International Conference and Exhibition on Cosmetology & Trichology

November 12-14, 2013 DoubleTree by Hilton Hotel Chicago-North Shore, IL, USA

Mostafa Soliman Kamel

Accepted Abstracts: J Clin Exp Dermatol Res

Abstract :

Back ground:The hormone 5-alpha dihydrotestosterone (DHT) is a metabolite of the "male" hormone testosterone. It is associated with two conditions common to men: benign prostate hypertrophy (BPH) and male pattern hair loss (MPHL). Both conditions have been successfully treated medically with a drug that lowers the level of DHT available to prostate tissue and hair follicles. The drug is called a 5-alpha reductase inhibitors drug that inhibits the action of the enzyme 5-alpha reductase that converts testosterone into DHT. Finasteride is identified as a 5-alpha reductase (type 2) inhibitor. This means that it inhibits the action of 5-alpha reductase (type 2), one of the two forms of the enzyme. Dutasteride, a more recently developed drug derivative from Finasteride, inhibits the action of both forms of the enzyme: type 1 5-alpha reductase and type 2, 5-alpha reductase. Aim: To evaluate the efficacy and safety of intradermal injection of 0.05% Dutasteride containing solution in comparison to 0.9% normal saline and lack of related studies. Patients & Methods: 52 male and female patients with MPHL types III, IV and V completed the study. They were randomly assigned to two groups: group 1 the treated group (n=28) and group II controls (n=28). Patients received seven injections at weeks 0, 1, 2, 3, 5, 7 and 11 and were evaluated at week 12. Results: The dutasteride-containing preparation was significantly more effective (p<0.05) than placebo. This was evident by three assessment methods; difference in hair count, professional independent observers? assessment and patients? self assessment. The less the duration of MPHL, the better was the response to dutasteride. Minimal side effects in the form of mild pain and headache were detected.

Biography :

Mostafa Soliman Kamel has completed his master?s from ceutices department faculty of Pharmacy, Cairo University and finished his MBA from American University in Cairo. He is member of many associations and organizations worldwide. He is the founder and director of Elixir Cosmo Group, one of leading cosmetic companies worldwide including three branches in Egypt, Saudi Arabia and U.A.E.